Consolidated statement of changes in equity for the year ended 31 May 2010 Corporate governance Financial statements Capital Attributable to Share Share redemption Other the owners Minority Total All figures in millions capital premium reserve reserves of the parent interest equity At 1 June 2009 5.9 151.9 0.3 85.2 243.3 92.5 335.8 Total comprehensive income for the year 82.1 82.1 40.7 122.8 Transactions with owners Share options settled from own shares 2.9 2.9 2.9 Exercise of Allscripts share options 0.8 0.8 Conversion of Allscripts 3.5% senior convertible debentures 3.5 3.5 5.7 9.2 Share-based payments 12.9 12.9 5.4 18.3 Deferred tax on share-based payments 7.2 7.2 4.7 11.9 At 31 May 2010 5.9 151.9 0.3 193.8 351.9 149.8 501.7 for the year ended 31 May 2009 Capital Attributable to Share Share redemption Other the owners Minority Total All figures in millions capital premium reserve reserves of the parent interest equity At 1 June 2008 5.5 67.3 0.3 5.2 78.3 78.3 Total comprehensive income for the year 94.5 94.5 12.3 106.8 Transactions with owners Shares issued in the year net of expenses 0.4 84.6 85.0 85.0 Dividends paid 23.9 23.9 23.9 Exercise of Allscripts share options 3.8 3.8 Buyback of Allscripts shares 15.2 15.2 1 Acquisitions 90.3 90.3 Share-based payments 9.9 9.9 2.3 12.2 Deferred tax on share-based payments 0.5 0.5 1.0 1.5 At 31 May 2009 5.9 151.9 0.3 85.2 243.3 92.5 335.8 1 Minority interest related acquisitions reserves include 67.9m for Allscripts and 22.4m for Misys Healthcare Systems.
On 18 March 2008, Misys launched a conditional placing of 42,857,143 new ordinary shares, with a nominal value of 1 penny per share the Placing Shares at a price of 175 pence per Placing Share.
During the year ended 31 May 2009, all of the Placing Shares were acquired by ValueAct Capital acting through its general partner VA Partners I, LLC pursuant to the underwriting commitment provided by it at the time of the placing.
Proceeds of the issue generated share premium of 84.6m net of issue expenses of 3.0m.
As required under IFRS 3, Misys has reassessed and finalised the provisional allocation of the Allscripts purchase price within the allowed 12 month period since the acquisition date and has restated the opening balances accordingly see note 16.
